TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06721468

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Child-centered nutrition phrases
Description: learn the phrase, trout helps your brain so you can learn and play either through researcher introduction or completing the About Trout! Pond to Plate curriculum

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Puzzle
Description: presented with a puzzle to solve each week
Study: NCT05788497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemorrane plus
Description: Hemorrane 10 mg/g rectal ointment + 30 mg/g benzocaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hemorrane
Description: Hemorrane 10 mg/g rectal ointment
Study: NCT06503991

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW)-delivered Hypertension Management Pilot (CHAMP)
Description: Clinic-based hypertension educational intervention delivered by a Community Health Worker.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control of Blood Pressure and Risk Attenuation (COBRA)
Description: Multi-component counseling program addressing patient education, provider training, coordination of care, and subsidizing care costs.
Study: NCT05513027

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Augmented Whole-body Scanning via Magnifying PET
Description: -Added at the end of the SOC PET/CT scan. Will take approximately 3-5 minutes longer.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: -Standard of care
Study: NCT06067295

Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study: NCT04856293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: A single 250 mg crizotinib dose of the FC formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: A single 250 mg crizotinib dose of the FC formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: A single 250 mg crizotinib dose of the encapsulated microsphere (eMS) formulation administered by sprinkling the contents into a dry glass vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: A single 250 mg crizotinib dose of the encapsulated microsphere (eMS) formulation administered by sprinkling the contents into a dry glass vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: A single 250 mg crizotinib dose of the single 250 mg crizotinib dose of the encapsulated microsphere (eMS) formulation (administered as intact capsules) . The intact capsules will be swallowed whole.
Study: NCT05961761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: propranolol 40 mg x2 daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: pembrolizumab 2 mg/kg every 3 weeks
Study: NCT04650932

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation
Description: Patients with idiopathic Parkinson's disease who have previously been implanted with the Boston Scientific VerciseTM DBS system for at least 3 months. These patients will already be receiving high-frequency dorsal STN stimulation as part of the standard of care for PD. Once patients have provided consent and are enrolled in this study, they will receive simultaneous low-frequency stimulation of the ventral STN to examine if there are any effects on cognitive performance.
Study: NCT05686967

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MitoQ
Description: MitoQ is a biochemically modified form of ubiquinol

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MitoQ
Description: MitoQ is a biochemically modified form of ubiquinol

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each placebo capsule contains inert excipient and is identical in appearance
Study: NCT05788497

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Rectal ointment
Study: NCT01796795

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle gel
Description: Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SR-T100 gel with 1.0% of SM
Description: Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SR-T100 gel with 2.3% of SM
Description: Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.
Study: NCT05061628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS006 as Monotherapy
Description: 1. JS006 as Monotherapy dose-escalation: JS006, 18/ 60/ 180/ 600/ 1800mg, IV infusion, every 3 weeks (q3w).~2. JS006 as Monotherapy dose-extension: JS006, 1 or 2 specific dose, IV infusion, every 3 weeks (q3w).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS006 in combination with Toripalimab
Description: 1. JS006 in combination with Toripalimab dose-escalation: JS006, 2 or 3 specific dose, IV infusion, every 3 weeks (q3w), combined with Toripalimab, 240mg, IV infusion, every 3 weeks (q3w).~2. JS006 in combination with Toripalimab dose-extension: JS006, 1 or 2 specific dose, IV infusion, every 3 weeks (q3w), combined with Toripalimab, 240mg, IV infusion, every 3 weeks (q3w).~3. JS006 in combination with Toripalimab indications expansion: JS006, RP2D, IV infusion, every 3 weeks(q3w), combined with Toripalimab, 240mg, IV infusion, every 3 weeks (q3w).
Study: NCT04738773

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: On the active drug group, naltrexone will be prescribed on flexible dose mode, receiving 50mg per day on the first week, with an increase of 25mg each week until a maximum of 200 mg per day or as much as tolerated by the patient.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05871359

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: The stimulator will be connected to two electrodes .The active electrode will be placed on the areas of the dorsal lateral pre-frontal cortex (DLPFC) contralateral to the more affected side.The other one on the supra orbital area.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: The stimulator will be connected to two electrodes .The active electrode will be placed on the areas of the dorsal lateral pre-frontal cortex (DLPFC) contralateral to the more affected side.The other one on the supra orbital area.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Dual task
Description: The Dual Task consists of walking for 20 minutes along a hallway, simultaneously patient has to answer to a different ecological cognitive (attention, fluences, calculation) and motor tasks (hold a tray, turn head, ecc..)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dual task
Description: The Dual Task consists of walking for 20 minutes along a hallway, simultaneously patient has to answer to a different ecological cognitive (attention, fluences, calculation) and motor tasks (hold a tray, turn head, ecc..)
Study: NCT06340438

Intervention type: OTHER
Group type: OTHER
Intervention: Histamine
Description: Histaminergic itch will be evoked by a 1% histamine solution. A droplet of histamine solution will be placed on the predetermined area on the forearm, and the SPT lancet will be pierced through the histamine with 120 g of pressure for 1-2 seconds.

Intervention type: OTHER
Group type: OTHER
Intervention: Cowhage
Description: 25 spicules will be inserted in the center of the predefined skin area on the mandibular area. The spicules will be gently rubbed for 15-20 seconds in circular motion to facilitate epidermal penetration.
Study: NCT05963087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab Dabrafenib Tislelizumab
Description: Dabrafenib 150mg，BID, Cetuximab 250mg/m2, Tislelizumab 200mg Treatment every three weeks
Study: NCT05383079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutetium-177 PSMA-I&T
Description: Patients will be given 7.4 GBq of 177Lu-PSMA every 6 weeks for up to 6 Cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223
Description: During dose escalation, doses of Radium-223 that will be administered include 27.5 kBq/kg and 55 kBq/kg. The maximum tolerated dose of Radium-223 will be used during dose expansion. Radium-223 will be given once every 6 weeks for up to 6 doses between day 1-5 of each Cycle.
Study: NCT05602415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib of 12mg will be administered orally, once daily, 2-days on/1-day off, until disease progression according to RECIST 1.1, death, unacceptable toxicity, or withdrawal of consent for any reasons. A cycle was considered to be 3 weeks. Anlotinib should be started 3-4 weeks after surgery, and continued for 3 months (4 cycles). The dose could be reduced to 8-10 mg once daily for patients who had grade 3 or 4 treatment-related toxicities, or for patients with intolerable grade 2 toxicity, despite maximum supportive care measures. If dose reduction was necessary, then the dose of anlotinib was reduced to 10 mg once daily. If further dose reduction was necessary, the dosage was reduced to 8 mg once daily. If the dosage of 8 mg once daily was not tolerable, then the patient stopped receiving anlotinib.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Postoperative radiotherapy would be performed. Postoperative intensity-modu¬lated RT (IMRT) will be performed (50 Gy in 2.0 Gy per fraction). No boost dose would be added if the margin was negative, a boost dose of 10-16 Gy would be added if the margin was microscopically positive, and a boost dose of 16-18 would be added if the margin was gross positive.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgery
Study: NCT05686967

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Moderate intensity aerobic exercise on the treadmill

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Aerobic exercise
Description: Moderate intensity aerobic exercise on the treadmill
Study: NCT05902039

Intervention type: OTHER
Intervention: MRI
Description: All participants underwent an MR examination on a 3T whole-body Prisma MRI system (Siemens, Erlangen, Germany) with a 64-channel head coil, and a 7T whole-body MAGNETOM MR system (Siemens, Erlangen, Germany) using a 32-channel receive/birdcage transmit head coil (NOVA medical). DP-pCASL, Multi-delay pCASL (MD-pCASL) was acquired to evaluate BBB function and cerebral perfusion. T1-weighted magnetization-prepared rapid gradient echo (T1w-MPRAGE) was scanned at both 3T and 7T for registration in the post-processing workflow. T2-weighted fluid-attenuated inversion recovery (T2w-FLAIR) and T2\*-weighted gradient echo (T2\*w-GRE) were acquired at 7T for high-resolution structural images and evaluation of lesions.
Study: NCT05868070

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional rehabilitation plus multimodal exercise
Description: Depending on the patient's condition, the intervention gradually progressed to passive, active assistive, active, and resistive exercise modes and the frequency of exercise interventions is gradually increased, and the application time of cycling/stepping is 20 minutes per session, and up to 3 times if there is no serious problem corresponding to the safety standards.
Study: NCT04190134

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Socially Assistive Robot for Low Vision Rehabilitation
Description: A socially assistive robot will be customized to engage in dialog and conversations to motivate and encourage optimal use of new magnification devices for reading at home by individuals with vision loss.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Socially Assistive Robot for Low Vision Rehabilitation
Description: A socially assistive robot will be customized to engage in dialog and conversations to motivate and encourage optimal use of new magnification devices for reading at home by individuals with vision loss.
Study: NCT06088433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Comparison of 12 month of ticagrelor SAPT（90mgBID\*1 month, followed by 60mgBID) versus 12 months of dual anti-platelet therapy (Aspirin 100mgQD+clopidogrel 75mgQD \* 1 month, followed by clopidogrel 75mgQD)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Comparison of 12 month of ticagrelor SAPT（90mgBID\*1 month, followed by 60mgBID) versus 12 months of dual anti-platelet therapy (Aspirin 100mgQD+clopidogrel 75mgQD \* 1 month, followed by clopidogrel 75mgQD)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Comparison of 12 month of ticagrelor SAPT（90mgBID\*1 month, followed by 60mgBID) versus 12 months of dual anti-platelet therapy (Aspirin 100mgQD+clopidogrel 75mgQD \* 1 month, followed by clopidogrel 75mgQD)
Study: NCT05457374

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PVE
Description: Portal vein embolization (PVE) mainly embolizes the portal vein of the resected liver lobe, causing the non-tumor lobe to proliferate, and after tumor lobectomy, the volume of the non-tumor lobe proliferates so that patients with hepatocellular carcinoma that could not be directly surgically resected are given the opportunity to be surgically resected

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LVD
Description: Combining PVE and Hepatic Vein Embolization (HVE) in the same procedure
Study: NCT05224505

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GNT0006
Description: Single intravenous infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Day 0: Placebo
Description: Single intravenous infusion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Day 0: GNT0006
Description: Single intravenous infusion

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Day 365 (year 1): Placebo
Description: Single intravenous infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Day 365 (year 1): GNT0006
Description: Single intravenous infusion
Study: NCT06332716

Intervention type: OTHER
Group type: OTHER
Intervention: Based on diagnostic and treatment guidelines/expert consensus, as well as clinical treatment experience, it is recommended that no more than 9 drugs be used for drug sensitivity testing each time.
Description: Based on diagnostic and treatment guidelines/expert consensus, as well as clinical treatment experience, it is recommended that no more than 9 drugs be used for drug sensitivity testing each time. The sending doctor can choose from the following relevant treatment drugs and confirm with the responsible researcher for drug sensitivity testing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Based on diagnostic and treatment guidelines/expert consensus, as well as clinical treatment experience, it is recommended that no more than 9 drugs be used for drug sensitivity testing each time.
Description: Based on diagnostic and treatment guidelines/expert consensus, as well as clinical treatment experience, it is recommended that no more than 9 drugs be used for drug sensitivity testing each time. The sending doctor can choose from the following relevant treatment drugs and confirm with the responsible researcher for drug sensitivity testing.
Study: NCT04210141

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: lyophilized BPI viper antivenom
Description: Antivenom

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: lyophilized BPI viper antivenom
Description: Antivenom
Study: NCT05943548

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Omuyambi
Description: HIV testing, referral, care linkage, and medication adherence support

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: HIV Testing and referral
Study: NCT05551182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicergoline
Description: The participants in both arms will receive nicergoline for treatment dysphagia 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicergoline
Description: The participants in both arms will receive nicergoline for treatment dysphagia 12 weeks.
Study: NCT04033718

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Inpatient lab bundling
Description: The investigators will provide patients a package of diagnostic tests at the time of admission to comprehensively assess for HIV coinfections and treatment failure. These labs are all recommended in advanced HIV guidelines but in this study we will provide all tests as a bundle rather than step-by-step as suggested in guidelines.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Inpatient lab bundling
Description: The investigators will provide patients a package of diagnostic tests at the time of admission to comprehensively assess for HIV coinfections and treatment failure. These labs are all recommended in advanced HIV guidelines but in this study we will provide all tests as a bundle rather than step-by-step as suggested in guidelines.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inpatient navigation
Description: Participants will be assigned a patient navigator who will support the patient and bedsider (treatment supporter/guardian) during the hospitalization. The navigator will be an HIV counselor who can provide counseling and health education, as well as support specimen transport, obtaining results, booking tests in other departments, linkages to ART clinic, and discharge planning
Study: NCT06025630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TUDCA
Description: Endoplasmic reticulum stress will be inhibited by chronic (8 weeks) oral ingestion of the dietary supplement tauroursodeoxycholic acid (TUDCA; 1,750 mg/day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pills containing microcrystalline cellulose will be ingested over the course of the 8 week intervention.
Study: NCT05222516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Broncho-Vaxom
Description: Daily administration of Broncho-Vaxom 3.5mg capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily administration of Placebo capsules
Study: NCT04996979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% Injectable Solution
Description: Local anaesthetic solution composed of ropivacaine 0.5%(intervention group)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Standard care
Study: NCT05890105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07853578
Description: PF-07853578 will be administered as oral solutions or suspensions as escalating single doses to be determined.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07853578
Description: PF-07853578 will be administered as oral solutions or suspensions as escalating single doses to be determined.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07853578
Description: PF-07853578 will be administered as oral solutions or suspensions as escalating single doses to be determined.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as oral solutions or suspensions as escalating single doses to be determined.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as oral solutions or suspensions as escalating single doses to be determined.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as oral solutions or suspensions as escalating single doses to be determined.
Study: NCT05898789

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CaRE@Home intervention
Description: participants randomized to the intervention arm will complete a virtual 8 week exercise and education program.
Study: NCT00749827

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bicarbonate Hydration
Description: Intravenous sodium bicarbonate (130 mEq/L) in 4.35% dextrose at 3.5 ml/Kg over 1 hour pre-contrast, followed by the same solution intravenously at 1 ml/Kg/hr for 6 hours. In all cases the maximum rate of fluid permitted is that for a body weight of 110 Kg. Intra-vascular low-osmolal or iso-osmolal contrast (according to operator or institution choice) will be used in the minimal dose needed to complete the required imaging.~Hypotonic hydration arm. Intravenous 5% dextrose in water at 3.5 ml/Kg over 1 hour pre-contrast followed by 0.9% saline intravenously at 1 ml/Kg/hr for 6 hours.
Study: NCT06677086

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment with BTL-899
Description: The treatment administration phase will consist of four (4) treatments, delivered 5-10 days apart. The applicators of BTL-899 device will be applied over the designated area. Each treatment session will last 30 minutes.
Study: NCT05406869

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed Sonic Balloon Dilatation Catheter and Pulsed Sonic Generater
Description: Deliver Pulsed Sonic Balloon Dilatation Catheter to the target vessel prior to placing a coronary stent or others
Study: NCT04940884

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervised exercise training
Description: SET Participants underwent 24 sessions of moderate-intensity exercise training (MICT) at 70% maximum predicted heart rate for 30 min in each session

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Description: All recruited subjects were instructed to walk \>=8000 steps per day in the community. Part of the participants were randomly assigned to underwent additional 24 sessions of supervised aerobic exercise training (SET) with the intensity at 70% of maximum predicted heart rate and the remaining participants follow the above home exercise training (HET) instruction without additional supervised exercise training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise training
Description: All recruited subjects were instructed to walk \>=8000 steps per day in the community. Part of the participants were randomly assigned to underwent additional 24 sessions of supervised aerobic exercise training (SET) with the intensity at 70% of maximum predicted heart rate and the remaining participants follow the above home exercise training (HET) instruction without additional supervised exercise training.